PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Gundersen Lutheran Center for Cancer and Blood

      RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping
      blood flow to the tumor.

      PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating
      patients who have stage IV melanoma.
    
Biological